Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 3
2007 2
2008 1
2009 2
2010 2
2012 1
2013 2
2014 3
2015 4
2016 4
2017 2
2018 4
2019 5
2020 1
2021 3
2022 11
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
PHGDH heterogeneity potentiates cancer cell dissemination and metastasis.
Rossi M, Altea-Manzano P, Demicco M, Doglioni G, Bornes L, Fukano M, Vandekeere A, Cuadros AM, Fernández-García J, Riera-Domingo C, Jauset C, Planque M, Alkan HF, Nittner D, Zuo D, Broadfield LA, Parik S, Pane AA, Rizzollo F, Rinaldi G, Zhang T, Teoh ST, Aurora AB, Karras P, Vermeire I, Broekaert D, Elsen JV, Knott MML, Orth MF, Demeyer S, Eelen G, Dobrolecki LE, Bassez A, Brussel TV, Sotlar K, Lewis MT, Bartsch H, Wuhrer M, Veelen PV, Carmeliet P, Cools J, Morrison SJ, Marine JC, Lambrechts D, Mazzone M, Hannon GJ, Lunt SY, Grünewald TGP, Park M, Rheenen JV, Fendt SM. Rossi M, et al. Among authors: dobrolecki le. Nature. 2022 May;605(7911):747-753. doi: 10.1038/s41586-022-04758-2. Epub 2022 May 18. Nature. 2022. PMID: 35585241 Free PMC article.
A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology.
Guillen KP, Fujita M, Butterfield AJ, Scherer SD, Bailey MH, Chu Z, DeRose YS, Zhao L, Cortes-Sanchez E, Yang CH, Toner J, Wang G, Qiao Y, Huang X, Greenland JA, Vahrenkamp JM, Lum DH, Factor RE, Nelson EW, Matsen CB, Poretta JM, Rosenthal R, Beck AC, Buys SS, Vaklavas C, Ward JH, Jensen RL, Jones KB, Li Z, Oesterreich S, Dobrolecki LE, Pathi SS, Woo XY, Berrett KC, Wadsworth ME, Chuang JH, Lewis MT, Marth GT, Gertz J, Varley KE, Welm BE, Welm AL. Guillen KP, et al. Among authors: dobrolecki le. Nat Cancer. 2022 Feb;3(2):232-250. doi: 10.1038/s43018-022-00337-6. Epub 2022 Feb 24. Nat Cancer. 2022. PMID: 35221336 Free PMC article.
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer.
Anurag M, Jaehnig EJ, Krug K, Lei JT, Bergstrom EJ, Kim BJ, Vashist TD, Huynh AMT, Dou Y, Gou X, Huang C, Shi Z, Wen B, Korchina V, Gibbs RA, Muzny DM, Doddapaneni H, Dobrolecki LE, Rodriguez H, Robles AI, Hiltke T, Lewis MT, Nangia JR, Nemati Shafaee M, Li S, Hagemann IS, Hoog J, Lim B, Osborne CK, Mani DR, Gillette MA, Zhang B, Echeverria GV, Miles G, Rimawi MF, Carr SA, Ademuyiwa FO, Satpathy S, Ellis MJ. Anurag M, et al. Among authors: dobrolecki le. Cancer Discov. 2022 Nov 2;12(11):2586-2605. doi: 10.1158/2159-8290.CD-22-0200. Cancer Discov. 2022. PMID: 36001024 Free PMC article.
Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer.
Bowling EA, Wang JH, Gong F, Wu W, Neill NJ, Kim IS, Tyagi S, Orellana M, Kurley SJ, Dominguez-Vidaña R, Chung HC, Hsu TY, Dubrulle J, Saltzman AB, Li H, Meena JK, Canlas GM, Chamakuri S, Singh S, Simon LM, Olson CM, Dobrolecki LE, Lewis MT, Zhang B, Golding I, Rosen JM, Young DW, Malovannaya A, Stossi F, Miles G, Ellis MJ, Yu L, Buonamici S, Lin CY, Karlin KL, Zhang XH, Westbrook TF. Bowling EA, et al. Among authors: dobrolecki le. Cell. 2021 Jan 21;184(2):384-403.e21. doi: 10.1016/j.cell.2020.12.031. Epub 2021 Jan 14. Cell. 2021. PMID: 33450205 Free PMC article.
Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer.
Zhao N, Cao J, Xu L, Tang Q, Dobrolecki LE, Lv X, Talukdar M, Lu Y, Wang X, Hu DZ, Shi Q, Xiang Y, Wang Y, Liu X, Bu W, Jiang Y, Li M, Gong Y, Sun Z, Ying H, Yuan B, Lin X, Feng XH, Hartig SM, Li F, Shen H, Chen Y, Han L, Zeng Q, Patterson JB, Kaipparettu BA, Putluri N, Sicheri F, Rosen JM, Lewis MT, Chen X. Zhao N, et al. Among authors: dobrolecki le. J Clin Invest. 2018 Apr 2;128(4):1283-1299. doi: 10.1172/JCI95873. Epub 2018 Feb 26. J Clin Invest. 2018. PMID: 29480818 Free PMC article.
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming.
Tian L, Goldstein A, Wang H, Ching Lo H, Sun Kim I, Welte T, Sheng K, Dobrolecki LE, Zhang X, Putluri N, Phung TL, Mani SA, Stossi F, Sreekumar A, Mancini MA, Decker WK, Zong C, Lewis MT, Zhang XH. Tian L, et al. Among authors: dobrolecki le. Nature. 2017 Apr 13;544(7649):250-254. doi: 10.1038/nature21724. Epub 2017 Apr 3. Nature. 2017. PMID: 28371798 Free PMC article.
Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer.
Gou X, Kim BJ, Anurag M, Lei JT, Young MN, Holt MV, Fandino D, Vollert CT, Singh P, Alzubi MA, Malovannaya A, Dobrolecki LE, Lewis MT, Li S, Foulds CE, Ellis MJ. Gou X, et al. Among authors: dobrolecki le. Cancer Res. 2023 Oct 2;83(19):3237-3251. doi: 10.1158/0008-5472.CAN-22-3484. Cancer Res. 2023. PMID: 37071495 Free PMC article.
PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition.
Li Y, Dobrolecki LE, Sallas C, Zhang X, Kerr TD, Bisht D, Wang Y, Awasthi S, Kaundal B, Wu S, Peng W, Mendillo ML, Lu Y, Jeter CR, Peng G, Liu J, Westin SN, Sood AK, Lewis MT, Das J, Yi SS, Bedford MT, McGrail DJ, Sahni N. Li Y, et al. Among authors: dobrolecki le. Cell Rep Med. 2023 Dec 19;4(12):101326. doi: 10.1016/j.xcrm.2023.101326. Cell Rep Med. 2023. PMID: 38118413 Free PMC article.
Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials.
Peehl DM, Badea CT, Chenevert TL, Daldrup-Link HE, Ding L, Dobrolecki LE, Houghton AM, Kinahan PE, Kurhanewicz J, Lewis MT, Li S, Luker GD, Ma CX, Manning HC, Mowery YM, O'Dwyer PJ, Pautler RG, Rosen MA, Roudi R, Ross BD, Shoghi KI, Sriram R, Talpaz M, Wahl RL, Zhou R. Peehl DM, et al. Among authors: dobrolecki le. Tomography. 2023 Mar 16;9(2):657-680. doi: 10.3390/tomography9020053. Tomography. 2023. PMID: 36961012 Free PMC article. Review.
RANK is a poor prognosis marker and a therapeutic target in ER-negative postmenopausal breast cancer.
Ciscar M, Trinidad EM, Perez-Chacon G, Alsaleem M, Jimenez M, Jimenez-Santos MJ, Perez-Montoyo H, Sanz-Moreno A, Vethencourt A, Toss M, Petit A, Soler-Monso MT, Lopez V, Gomez-Miragaya J, Gomez-Aleza C, Dobrolecki LE, Lewis MT, Bruna A, Mouron S, Quintela-Fandino M, Al-Shahrour F, Martinez-Aranda A, Sierra A, Green AR, Rakha E, Gonzalez-Suarez E. Ciscar M, et al. Among authors: dobrolecki le. EMBO Mol Med. 2023 Apr 11;15(4):e16715. doi: 10.15252/emmm.202216715. Epub 2023 Mar 7. EMBO Mol Med. 2023. PMID: 36880458 Free PMC article.
56 results